• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Total, Bioavailable, and Free 25(OH)D Relationship with Indices of Bone Health in Elderly: A Randomized Controlled Trial.总、生物可利用和游离 25(OH)D 与老年人群骨健康指标的关系:一项随机对照试验。
J Clin Endocrinol Metab. 2021 Jan 23;106(2):e990-e1001. doi: 10.1210/clinem/dgaa780.
2
Association of 25-hydroxyvitamin D with areal and volumetric measures of bone mineral density and parathyroid hormone: impact of vitamin D-binding protein and its assays.25-羟基维生素D与骨矿物质密度的面积和体积测量值及甲状旁腺激素的关联:维生素D结合蛋白及其检测方法的影响
Osteoporos Int. 2016 Feb;27(2):617-26. doi: 10.1007/s00198-015-3296-6. Epub 2015 Sep 10.
3
Free 25(OH)D and Calcium Absorption, PTH, and Markers of Bone Turnover.游离25(OH)D与钙吸收、甲状旁腺激素及骨转换标志物
J Clin Endocrinol Metab. 2015 Nov;100(11):4140-5. doi: 10.1210/jc.2015-2548. Epub 2015 Aug 27.
4
Screening for Vitamin D Deficiency in Black Americans: Comparison of Total, Free, Bioavailable 25 Hydroxy Vitamin D Levels with Parathyroid Hormone Levels and Bone Mineral Density.美国黑人维生素 D 缺乏症筛查:甲状旁腺激素水平和骨密度与总、游离、生物可利用 25 羟维生素 D 水平的比较。
J Nutr Health Aging. 2018;22(9):1045-1050. doi: 10.1007/s12603-018-1080-y.
5
Bioavailable vitamin D levels are reduced and correlate with bone mineral density and markers of mineral metabolism in adults with nephrotic syndrome.肾病综合征成人患者的生物可利用维生素D水平降低,且与骨矿物质密度及矿物质代谢标志物相关。
Nephrology (Carlton). 2016 Jun;21(6):483-9. doi: 10.1111/nep.12638.
6
The levels of bone turnover markers 25(OH)D and PTH and their relationship with bone mineral density in postmenopausal women in a suburban district in China.中国某郊区绝经后女性骨转换标志物25(OH)D和甲状旁腺激素水平及其与骨密度的关系
Osteoporos Int. 2017 Jan;28(1):211-218. doi: 10.1007/s00198-016-3692-6. Epub 2016 Jul 28.
7
[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].3、4、5期慢性肾脏病(未透析)患者矿物质代谢的变化
Nefrologia. 2008;28 Suppl 3:67-78.
8
Effect of increasing doses of vitamin D on bone mineral density and serum N-terminal telopeptide in elderly women: a randomized controlled trial.增加维生素 D 剂量对老年女性骨密度和血清 N 端肽的影响:一项随机对照试验。
J Intern Med. 2018 Dec;284(6):685-693. doi: 10.1111/joim.12825. Epub 2018 Sep 17.
9
Effectiveness and safety of vitamin D in relation to bone health.维生素D对骨骼健康的有效性与安全性。
Evid Rep Technol Assess (Full Rep). 2007 Aug(158):1-235.
10
Vitamin D3 Dose Requirement That Raises 25-Hydroxyvitamin D to Desirable Level in Overweight and Obese Elderly.超重和肥胖老年人中使 25-羟维生素 D 达到理想水平所需的维生素 D3 剂量。
J Clin Endocrinol Metab. 2021 Aug 18;106(9):e3644-e3654. doi: 10.1210/clinem/dgab296.

引用本文的文献

1
Variation of bone-related and inflammatory biomarkers after a half-marathon running in trained subjects.训练有素的受试者在半程马拉松跑步后骨相关和炎症生物标志物的变化。
Eur J Appl Physiol. 2025 Jul 1. doi: 10.1007/s00421-025-05874-3.
2
Clinical Practice Guidelines of the Latin American Federation of Endocrinology for the use of vitamin D in the maintenance of bone health: recommendations for the Latin American context.拉丁美洲内分泌学会临床实践指南:维生素 D 在维持骨骼健康中的应用:拉丁美洲建议。
Arch Osteoporos. 2024 Jun 8;19(1):46. doi: 10.1007/s11657-024-01398-z.
3
Consensus Statement on Vitamin D Status Assessment and Supplementation: Whys, Whens, and Hows.维生素 D 状态评估和补充的共识声明:为何、何时以及如何。
Endocr Rev. 2024 Sep 12;45(5):625-654. doi: 10.1210/endrev/bnae009.
4
Circulating total 25(OH)D and calculated free 25(OH)D in professional academy footballers at a northerly latitude in the UK.英国北部纬度地区职业足球运动员的循环总25(羟)维生素D和计算得出的游离25(羟)维生素D
Biol Sport. 2024 Mar;41(2):201-208. doi: 10.5114/biolsport.2024.131822. Epub 2023 Nov 10.
5
Free and bioavailable 25-hydroxyvitamin D thresholds for bone metabolism and their associations with metabolic syndrome in Chinese women of childbearing age.中国育龄女性骨代谢的游离及生物可利用25-羟维生素D阈值及其与代谢综合征的关联。
Front Nutr. 2023 Aug 31;10:1131140. doi: 10.3389/fnut.2023.1131140. eCollection 2023.
6
Total and free 25-hydroxyvitamin D concentrations and risk of urinary incontinence in women participating in Nurses Health Studies I & II.妇女参与护士健康研究 I 和 II 中总 25-羟维生素 D 浓度和尿失禁风险。
Am J Med Sci. 2023 Nov;366(5):330-336. doi: 10.1016/j.amjms.2023.08.007. Epub 2023 Aug 20.
7
Vitamin D and Calcium in Osteoporosis, and the Role of Bone Turnover Markers: A Narrative Review of Recent Data from RCTs.维生素D和钙在骨质疏松症中的作用以及骨转换标志物的作用:来自随机对照试验的最新数据的叙述性综述
Diseases. 2023 Feb 8;11(1):29. doi: 10.3390/diseases11010029.
8
Rapidly Increasing Serum 25(OH)D Boosts the Immune System, against Infections-Sepsis and COVID-19.血清 25(OH)D 水平迅速升高可增强免疫系统,预防感染-脓毒症和 COVID-19。
Nutrients. 2022 Jul 21;14(14):2997. doi: 10.3390/nu14142997.
9
Absence of causal association between Vitamin D and bone mineral density across the lifespan: a Mendelian randomization study.维生素 D 与寿命期内骨矿物质密度之间不存在因果关系:一项孟德尔随机化研究。
Sci Rep. 2022 Jun 21;12(1):10408. doi: 10.1038/s41598-022-14548-5.
10
Free and Bioavailable Vitamin D Levels of Patients with Type 1 Diabetes Mellitus and Association with Bone Metabolism.1型糖尿病患者的游离及生物可利用维生素D水平及其与骨代谢的关系
J Diabetes Metab Disord. 2022 Apr 5;21(1):689-695. doi: 10.1007/s40200-022-01032-0. eCollection 2022 Jun.

本文引用的文献

1
Vitamin D Binding Protein: A Historic Overview.维生素D结合蛋白:历史概述
Front Endocrinol (Lausanne). 2020 Jan 10;10:910. doi: 10.3389/fendo.2019.00910. eCollection 2019.
2
Time trends and predictors of hypovitaminosis D across the life course: 2009-2016.生命历程中维生素 D 缺乏症的时间趋势和预测因素:2009-2016 年。
Metabolism. 2020 Apr;105:154138. doi: 10.1016/j.metabol.2020.154138. Epub 2020 Jan 7.
3
Effects of Supplemental Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and OmegA-3 TriaL (VITAL).维生素D与Omega-3试验(VITAL)中补充维生素D对女性和男性骨骼健康结局的影响
J Bone Miner Res. 2020 May;35(5):883-893. doi: 10.1002/jbmr.3958. Epub 2020 Jan 30.
4
Relationship of Total and Free 25-Hydroxyvitamin D to Biomarkers and Metabolic Indices in Healthy Children.健康儿童中总25-羟基维生素D和游离25-羟基维生素D与生物标志物及代谢指标的关系
J Clin Endocrinol Metab. 2020 Apr 1;105(4):e1631-40. doi: 10.1210/clinem/dgz230.
5
Vitamin D and cardiovascular disorders.维生素 D 与心血管疾病。
Osteoporos Int. 2019 Nov;30(11):2167-2181. doi: 10.1007/s00198-019-05098-0. Epub 2019 Aug 11.
6
Effect of vitamin D supplementation on total and free 25 hydroxyvitamin D and parathyroid hormone. An analysis of two randomized controlled trials.维生素 D 补充对总 25 羟维生素 D 和甲状旁腺激素的影响。两项随机对照试验的分析。
J Intern Med. 2019 Dec;286(6):651-659. doi: 10.1111/joim.12950. Epub 2019 Jul 29.
7
Vitamin D Binding Protein, Total and Free Vitamin D Levels in Different Physiological and Pathophysiological Conditions.不同生理和病理生理条件下的维生素D结合蛋白、总维生素D和游离维生素D水平
Front Endocrinol (Lausanne). 2019 May 28;10:317. doi: 10.3389/fendo.2019.00317. eCollection 2019.
8
Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society.目前欧洲和中东国家的维生素 D 状况以及预防维生素 D 缺乏的策略:欧洲钙化组织学会的立场声明。
Eur J Endocrinol. 2019 Apr;180(4):P23-P54. doi: 10.1530/EJE-18-0736.
9
Randomized controlled trial of vitamin D supplementation in older people to optimize bone health.维生素 D 补充剂治疗老年人以优化骨骼健康的随机对照试验。
Am J Clin Nutr. 2019 Jan 1;109(1):207-217. doi: 10.1093/ajcn/nqy280.
10
Measured free 25-hydroxyvitamin D in healthy children and relationship to total 25-hydroxyvitamin D, calculated free 25-hydroxyvitamin D and vitamin D binding protein.健康儿童中游离25-羟基维生素D的测定及其与总25-羟基维生素D、计算所得游离25-羟基维生素D和维生素D结合蛋白的关系。
Clin Biochem. 2018 Nov;61:23-27. doi: 10.1016/j.clinbiochem.2018.08.007. Epub 2018 Aug 18.

总、生物可利用和游离 25(OH)D 与老年人群骨健康指标的关系:一项随机对照试验。

Total, Bioavailable, and Free 25(OH)D Relationship with Indices of Bone Health in Elderly: A Randomized Controlled Trial.

机构信息

Scholars in Health Research Program, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.

Department of Internal Medicine, Division of Endocrinology, Calcium Metabolism and Osteoporosis Program, Beirut, Lebanon.

出版信息

J Clin Endocrinol Metab. 2021 Jan 23;106(2):e990-e1001. doi: 10.1210/clinem/dgaa780.

DOI:10.1210/clinem/dgaa780
PMID:33280041
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7823248/
Abstract

CONTEXT

Questions regarding the superiority of free and bioavailable 25-hydroxyvitamin D [25(OH)D] in predicting health outcomes remain unresolved.

OBJECTIVE

This study investigates the impact of vitamin D variables-total, bioavailable, or free 25(OH)D-on indices of bone and mineral metabolism, at baseline and in response to 2 vitamin D doses.

DESIGN

Our objectives are implemented as exploratory analyses on data collected in a 1-year, double-blind, randomized controlled trial completed in July 2014.

SETTING

Participants were recruited from 3 major hospitals in an ambulatory setting.

PARTICIPANTS

Participants were >65 years of age, overweight, and had a baseline serum 25(OH)D between 10 and 30 ng/mL. A total of 221 participants completed the study.

INTERVENTION

Subjects were randomized to receive calcium and oral vitamin D3 (600 IU/day or 3750 IU/day) supplementation.

RESULTS

Participants who received the higher vitamin D dose had levels that were 1.3- to 1.4-fold higher than those taking the lower dose, for all variables (P value < 0.001). Serum values of bioavailable and free 25(OH)D were associated with total 25(OH)D, with r values of 0.942 and 0.943, respectively (P value < 0.001). Parathyroid hormone (PTH) was negatively associated with all vitamin D variables, with correlation coefficients ranging from -0.22 to -0.25, while calcium and bone turnover markers (carboxy-terminal collagen crosslinks and osteocalcin) did not. Only total 25(OH)D had a positive relationship with % change bone mineral density (BMD) at the femoral neck at 12 months, while only free and bioavailable 25(OH) had a positive relationship with % change total body BMD at 12 months.

CONCLUSION

Calculated free and bioavailable 25(OH)D do not appear to be superior to total 25(OH)D in predicting indices of bone health in an elderly population.

摘要

背景

关于游离和生物可利用 25-羟维生素 D [25(OH)D]在预测健康结果方面的优势的问题仍未得到解决。

目的

本研究调查了维生素 D 变量(总、生物可利用或游离 25(OH)D)在基线和对 2 种维生素 D 剂量的反应时对骨和矿物质代谢指标的影响。

设计

我们的目标是在 2014 年 7 月完成的为期 1 年、双盲、随机对照试验的数据中进行探索性分析。

地点

参与者是在门诊环境中从 3 家大医院招募的。

参与者

参与者年龄大于 65 岁,超重,基线血清 25(OH)D 在 10 至 30ng/mL 之间。共有 221 名参与者完成了研究。

干预

受试者随机接受钙和口服维生素 D3(600IU/天或 3750IU/天)补充。

结果

接受较高维生素 D 剂量的参与者的所有变量(P 值均<0.001)水平比接受较低剂量的参与者高 1.3-1.4 倍。生物可利用和游离 25(OH)D 的血清值与总 25(OH)D 相关,r 值分别为 0.942 和 0.943(P 值均<0.001)。甲状旁腺激素(PTH)与所有维生素 D 变量呈负相关,相关系数范围为-0.22 至-0.25,而钙和骨转换标志物(羧基末端胶原蛋白交联和骨钙素)则没有。只有总 25(OH)D 与 12 个月时股骨颈的骨密度(BMD)百分比变化呈正相关,而游离和生物可利用的 25(OH)D 仅与 12 个月时全身 BMD 的百分比变化呈正相关。

结论

在老年人群中,计算的游离和生物可利用 25(OH)D 似乎并不优于总 25(OH)D 来预测骨健康指标。